BAMS
Bellevue Asset Management (Switzerland) Portfolio holdings
AUM
$656M
1-Year Return
11.48%
This Quarter Return
-14.54%
1 Year Return
+11.48%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$613M
AUM Growth
-$108M
(-15%)
Cap. Flow
+$5.9M
Cap. Flow
% of AUM
0.96%
Top 10 Holdings %
Top 10 Hldgs %
30.19%
Holding
150
New
11
Increased
47
Reduced
31
Closed
17
Top Buys
| 1 |
Supernus Pharmaceuticals
SUPN
|
$4.49M |
| 2 |
Amgen
AMGN
|
$3.2M |
| 3 |
Larimar Therapeutics
LRMR
|
$3.2M |
| 4 |
INSY
Insys Therapeutics, Inc.
INSY
|
$2.56M |
| 5 |
Incyte
INCY
|
$2.21M |
Top Sells
| 1 |
RCPT
RECEPTOS INC COM STK (DE)
RCPT
|
$6.46M |
| 2 |
Cardinal Health
CAH
|
$3.3M |
| 3 |
KITE
Kite Pharma, Inc.
KITE
|
$3.09M |
| 4 |
MDVN
MEDIVATION, INC.
MDVN
|
$2.98M |
| 5 |
Alkermes
ALKS
|
$2.96M |
Sector Composition
| 1 | Healthcare | 91.86% |
| 2 | Financials | 0.95% |
| 3 | Industrials | 0.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
51
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $4.36M | 0.71% |
220,000
+70,000
| +47% | +$1.39M |
|
52
Elevance Health
ELV
$69.4B
| $4.2M | 0.69% |
30,000
| – | – |
|
53
Agios Pharmaceuticals
AGIO
$2.1B
| $3.81M | 0.62% |
54,000
+13,000
| +32% | +$918K |
|
54
Bristol-Myers Squibb
BMY
$95B
| $3.55M | 0.58% |
60,000
| – | – |
|
|
55
Alkermes
ALKS
$4.77B
| $3.46M | 0.56% |
59,000
-50,500
| -46% | -$2.96M |
|
56
Halozyme
HALO
$8.59B
| $3.3M | 0.54% |
246,000
+154,384
| +169% | +$2.07M |
|
|
CERN
57
DELISTED
Cerner Corp
CERN
| $3.3M | 0.54% |
55,000
| – | – |
|
|
AKRX
58
DELISTED
Akorn, Inc.
AKRX
| $3.21M | 0.52% |
112,470
-15,580
| -12% | -$444K |
|
|
59
Larimar Therapeutics
LRMR
$331M
| $3.2M | 0.52% |
+8,333
| New | +$3.2M |
|
60
Hologic
HOLX
$14.8B
| $3.17M | 0.52% |
81,000
| – | – |
|
61
HCA Healthcare
HCA
$96.3B
| $3.09M | 0.5% |
40,000
| – | – |
|
62
Merck
MRK
$210B
| $2.96M | 0.48% |
62,880
-10,480
| -14% | -$494K |
|
63
Dentsply Sirona
XRAY
$2.86B
| $2.95M | 0.48% |
58,400
| – | – |
|
64
Eli Lilly
LLY
$666B
| $2.93M | 0.48% |
35,000
+15,000
| +75% | +$1.26M |
|
|
ACHN
65
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $2.9M | 0.47% |
420,000
+44,000
| +12% | +$304K |
|
66
Masimo
MASI
$7.77B
| $2.89M | 0.47% |
75,000
| – | – |
|
|
ARIA
67
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $2.89M | 0.47% |
495,000
| – | – |
|
|
SRCL
68
DELISTED
Stericycle Inc
SRCL
| $2.79M | 0.45% |
20,000
+5,000
| +33% | +$697K |
|
69
Cooper Companies
COO
$13.5B
| $2.75M | 0.45% |
74,000
| – | – |
|
|
VAR
70
DELISTED
Varian Medical Systems, Inc.
VAR
| $2.73M | 0.45% |
42,194
-5,702
| -12% | -$369K |
|
71
Pfizer
PFE
$140B
| $2.67M | 0.44% |
89,590
-15,810
| -15% | -$471K |
|
72
Nektar Therapeutics
NKTR
$684M
| $2.65M | 0.43% |
16,000
+2,667
| +20% | +$442K |
|
|
NVDQ
73
DELISTED
Novadaq Technologies Inc.
NVDQ
| $2.61M | 0.43% |
250,000
+174,402
| +231% | +$1.82M |
|
74
Neurocrine Biosciences
NBIX
$13.9B
| $2.59M | 0.42% |
65,000
| – | – |
|
75
Alnylam Pharmaceuticals
ALNY
$59.4B
| $2.57M | 0.42% |
32,000
-22,000
| -41% | -$1.77M |
|